肌层浸润性膀胱癌患者新辅助化疗使用模式及质量分析
基于SEER-Medicare数据库纳入2001至2011年临床TII-IV期膀胱癌行根治性膀胱切除术患者2738例,其中344例(12.6%)接受新辅助化疗。最常用方案为吉西他滨-顺铂(45.3%),M-VAC与II期患者总生存改善显著相关(HR 0.24,95%CI 0.07-0.86;p=0.030)。新辅助化疗使用不足且方案质量与指南推荐不一致。
要点
- 根治性膀胱切除术患者中仅12.6%接受新辅助化疗,研究期间使用率从5.7%升至17.3%。
- 最常用方案为吉西他滨-顺铂(45.3%),其次为吉西他滨-卡铂(24.1%)和M-VAC(6.7%)。
- II期患者中M-VAC与总生存改善显著相关(HR 0.24,95%CI 0.07-0.86;p=0.030)。
核心结论
- 新辅助化疗使用不足,且所用方案质量与指南推荐不一致。
- 这些发现对解读基于人群的化疗使用数据及外推生存结局具有重要意义。
研究设计与样本
- 使用监测、流行病学和最终结果(SEER)-Medicare关联数据库,识别2001年1月1日至2011年12月31日诊断为临床TII-IV期膀胱癌的患者。
- 共2738例接受根治性膀胱切除术的患者纳入分析。
主要发现
- 2738例接受根治性膀胱切除术的患者中,344例(12.6%)接受新辅助化疗。
- 最常用药物为吉西他滨(72.3%)、顺铂(55.2%)和卡铂(31.1%)。
- 最常用方案为吉西他滨-顺铂(45.3%)、吉西他滨-卡铂(24.1%)和甲氨蝶呤、长春碱、多柔比星及顺铂(M-VAC;6.7%)。
- 研究期间新辅助化疗使用率从2001年的5.7%增至2011年的17.3%(p<0.001)。
- 在II期膀胱癌患者中,M-VAC使用与更好的总生存显著相关(HR 0.24,95%CI 0.07-0.86;p=0.030)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 局限性包括回顾性分析控制选择偏倚的能力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant chemotherapy is underutilized in bladder cancer patients who undergo radical cystectomy. However, the quality of regimens used in this setting remains largely unknown. OBJECTIVE: To determine utilization treatment patterns and survival outcomes according to regimens administered. DESIGN, SETTING, AND PATIENTS: We used the Surveillance, Epidemiology and End Results (SEER)-Medicare linked database to identify patients diagnosed with clinical stage TII-IV bladder cancer from January 1, 2001 to December 31, 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Temporal trends were assessed using the Cochran-Armitage test. Multivariable logistic regression models were used to identify predictors for neoadjuvant chemotherapy use. Cox proportional hazards models were used to compare overall survival according to regimens administered. RESULTS AND LIMITATIONS: Of 2738 patients treated with radical cystectomy, 344 (12.6%) received neoadjuvant chemotherapy. The agents most commonly used were gemcitabine (72.3%), cisplatin (55.2%), and carboplatin (31.1%). The regimens most commonly used were gemcitabine-cisplatin (45.3%), gemcitabine-carboplatin (24.1%), and methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC; 6.7%). Use of neoadjuvant chemotherapy more than tripled during the study period, from 5.7% in 2001 to 17.3% in 2011 (p<0.001). The quality of the regimen administered impacted survival outcomes, as M-VAC use was significantly associated with better overall survival among patients diagnosed with stage II bladder cancer (hazard ratio 0.24, 95% confidence interval 0.07-0.86; p=0.030]. Limitations include the limited ability of retrospective analysis to control for selection bias. CONCLUSIONS: Neoadjuvant chemotherapy was underused, and the quality of neoadjuvant chemotherapy regimens administered for bladder cancer was inconsistent with guideline recommendations. These findings are important when interpreting population-based data on the use of chemotherapy and extrapolating survival outcomes. PATIENT SUMMARY: In a large population-based study, 12.6% of patients undergoing radical cystectomy for bladder cancer received neoadjuvant chemotherapy, half of whom received guideline-recommended regimens. The quality of the regimen impacted survival outcomes, as use of cisplatin-based chemotherapy was significantly associated with better overall survival among patients diagnosed with stage II bladder cancer. However, <1% of radical cystectomy patients received this regimen.
引用
- Huo J, Ray-Zack MD, Shan Y, et al. Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer. Eur Urol Oncol. 2018. PMID: 31411998. doi:10.1016/j.euo.2018.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。